UNSPSC 51204102: Rilonacept

This classification denotes a biological response modifier with the molecular formula C9030H13932N2400O2670S74, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8K80YB5GMG, more generally known as rilonacept. European Medicines Agency schedules rilonacept in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB28994. The term RILONACEPT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21, No. 1, 2007, list 57.

Most nations, for tariff and trade purposes, schedule Rilonacept under HS 30021020 and SITC 54163. SMILES:. As of Q4 2014, RILONACEPT remains US FDA's Preferred Term for this commodity.. Rilonacept bears US NLM identifiers UMLS ID C2343589 and NCI Concept Code C84137.

UNSPSC 51204102 Rilonacept, a Commodity code, shows a significant mismatch between the code's nominal scope and the actual work state and local governments are buying under it. The code targets rilonacept, a specific biopharmaceutical treatment, but recent state and local solicitations tagged to this code involve medical and first aid supplies, naloxone and drug deactivation systems, generic pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs — none of which are rilonacept. The issuing bodies include county health departments, city fire rescue divisions, state health and human services agencies, and cooperative purchasing alliances serving multiple states. While the source documents pharmaceutical procurement across a range of modalities — traditional sealed bidding for emergency medical supplies, request-for-information market research for direct-to-manufacturer arrangements, and multi-state cooperative RFPs for generic drug sourcing — the underlying activity does not align with the rilonacept commodity designation.

Recent opportunities appear concentrated in Florida and Texas, with multi-state cooperative activity through Minnesota. Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with a response deadline of July 26, 2023. The City of Tampa issued an IFB (26P00145) on March 25, 2026 for 169 line items of medical and first aid supplies including respiratory equipment and cardiac monitoring devices for the Tampa Fire Department Rescue Division, with a response deadline of March 13, 2026 and an estimated contract value of $700,000. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Department of Administration, through MMCAP, issued an RFP (S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and availability required by May 15, 2026. The code shows activity but exhibits poor relevance to rilonacept specifically — this coding mismatch warrants review before allocating pursuit resources.